Future therapeutic strategies aimed at modulating TNF-α signalling hold promise for improving outcomes in patients with EHEC-induced neurological complications, including haemolytic uremic syndrome (HUS) and central nervous system (CNS) involvement. This evidence concerns the gene TNF and hemolytic-uremic syndrome.